来那度胺联合阿法依泊汀对比来那度胺单药治疗重组促红细胞生成素难治性骨髓增生异常综合征
该III期美国组间试验将195例低危、非del(5q)且对重组促红细胞生成素难治或获益概率低的MDS贫血患者随机分入来那度胺联合阿法依泊汀组或来那度胺单药组。四周期后联合组主要红系缓解率显著高于单药组(28.3% vs 11.5%,P=.004),中位缓解持续时间分别为23.8个月与13个月。
要点
- 来那度胺联合阿法依泊汀可恢复对促红细胞生成素的敏感性,提高主要红系缓解率。
- 联合组主要红系缓解持续时间达23.8个月,优于单药组的13个月。
- 来那度胺单药无应答者交叉加用阿法依泊汀后26.3%获主要红系缓解。
核心结论
- 在生长因子不敏感的低危、非del(5q)MDS中,来那度胺可恢复对重组促红细胞生成素的敏感性,联合治疗的主要红系缓解率及缓解持续时间均显著优于来那度胺单药。
研究设计与样本
- III期美国组间随机对照试验,按血清促红细胞生成素浓度和既往促红细胞生成素治疗分层。
- 共195例可评估患者随机分配,99例接受来那度胺联合阿法依泊汀,96例接受来那度胺单药。
主要发现
- 四周期治疗后,联合组主要红系缓解率为28.3%,单药组为11.5%(P=.004)。
- 完成16周治疗的136例患者中,联合组与单药组主要红系缓解率分别为38.9%与15.6%(P=.004)。
- 微小红系缓解率分别为18.2%与20.8%,总体红系缓解率分别为46.5%与32.3%。
- 来那度胺无应答者中38例交叉加用阿法依泊汀,10例(26.3%)获主要红系缓解。
- 联合治疗中位主要红系缓解持续时间为23.8个月,单药组为13个月。
关键数值与推荐
- 主要终点为四周期治疗后主要红系缓解率:联合组28.3% vs 单药组11.5%(P=.004)。
- 完成16周治疗者主要红系缓解率:联合组38.9% vs 单药组15.6%(P=.004)。
- 总体红系缓解率:联合组46.5% vs 单药组32.3%。
- 中位主要红系缓解持续时间:联合组23.8个月 vs 单药组13个月。
临床怎么用
- 对重组促红细胞生成素难治或低获益概率的低危、非del(5q)MDS贫血患者,可考虑来那度胺联合阿法依泊汀以提高红系缓解率并延长缓解持续时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Impaired response to erythropoietin underlies ineffective erythropoiesis and anemia in myelodysplastic syndromes (MDS). We investigated whether treatment with lenalidomide (LEN), which augments erythropoietin receptor signaling in vitro, can restore and improve hemoglobin response to epoetin (EPO) alfa in patients with lower-risk, non-del(5q) MDS who have anemia that is refractory to or have low probability of benefit from treatment with recombinant erythropoietin. METHODS: In a phase III, US intergroup trial, we randomly assigned patients to receive either LEN and EPO alfa or LEN alone following stratification by serum erythropoietin concentration and prior erythropoietin treatment. RESULTS: A total of 195 evaluable patients were randomly assigned: 99 patients to the LEN-EPO alfa cohort and 96 to LEN alone. After four cycles of treatment, the primary end point of major erythroid response (MER) was significantly higher (28.3%) with the combination compared with LEN alone (11.5%) (P = .004). Among 136 patients who completed 16 weeks of study treatment, 38.9% and 15.6% achieved MER, respectively (P = .004). Additionally, minor erythroid response was achieved in 18.2% and 20.8% of patients, for an overall erythroid response rate of 46.5% versus 32.3%. Among LEN nonresponders, 38 crossed over to the addition of EPO alfa with 10 patients (26.3%) achieving a MER. Responses to the combined treatment were highly durable with a median MER duration of 23.8 months compared with 13 months with LEN alone. CONCLUSION: LEN restores sensitivity to recombinant erythropoietin in growth factor-insensitive, lower-risk, non-del(5q) MDS, to yield a significantly higher rate and duration of MER compared with LEN alone (funded by the National Cancer Institute; E2905 ClinicalTrials.gov identifier: NCT02048813).
引用
- List AF, Sun Z, Verma A, et al. Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. J Clin Oncol. 2021. PMID: 33439748. doi:10.1200/JCO.20.01691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。